Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer.
carbon ion therapy
hypoxia activated prodrug
pancreatic cancer
proton therapy
radiosensitizer
stereotactic body radiation therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Jan 2020
09 Jan 2020
Historique:
received:
18
12
2019
revised:
03
01
2020
accepted:
06
01
2020
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
16
1
2020
Statut:
epublish
Résumé
Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact on overall survival. Hypoxia-activated prodrugs are the latest strategy to reintroduce oxygenation to radioresistant cells harbouring in pancreatic cancer. This paper reviews the current status of photon and particle radiation therapy for pancreatic cancer in combination with systemic therapies and hypoxia activators. The current effectiveness of management of pancreatic cancer was systematically evaluated from MEDLINE Limited published data suggest pancreatic cancer patients undergoing carbon ion therapy and proton therapy achieve a comparable median survival time (25.1 months and 25.6 months, respectively) and 1-year overall survival rate (84% and 77.8%). Inconsistencies in methodology, recording parameters and protocols have prevented the safety and technical aspects of particle therapy to be fully defined yet. There is an increasing requirement to tackle unmet clinical demands of pancreatic cancer, particularly the lack of synergistic therapies in the advancing space of radiation oncology.
Identifiants
pubmed: 31936565
pii: cancers12010163
doi: 10.3390/cancers12010163
pmc: PMC7017270
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest
Références
Radiother Oncol. 2000 Aug;56(2):265-70
pubmed: 10927148
BMC Cancer. 2012 Oct 25;12:496
pubmed: 23098625
J Gastrointest Oncol. 2013 Dec;4(4):E33-4
pubmed: 24294518
Cancer. 2009 Feb 1;115(3):665-72
pubmed: 19117351
Crit Rev Oncol Hematol. 2016 Jul;103:49-61
pubmed: 27233119
BMC Cancer. 2016 Oct 19;16(1):812
pubmed: 27756258
Mol Cancer Ther. 2012 Mar;11(3):740-51
pubmed: 22147748
Int J Nanomedicine. 2018 Oct 18;13:6551-6574
pubmed: 30425475
Clin Cancer Res. 2007 Jul 1;13(13):3922-32
pubmed: 17606726
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):919-22
pubmed: 11072146
Radiother Oncol. 2012 Apr;103(1):25-31
pubmed: 22300608
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):918-25
pubmed: 25585785
Acta Oncol. 2013 Apr;52(3):498-505
pubmed: 23477361
Pancreas. 2004 Apr;28(3):330-4
pubmed: 15084982
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42
pubmed: 20171803
Am J Clin Oncol. 2017 Apr;40(2):152-157
pubmed: 25171298
J Clin Oncol. 2014 Oct 10;32(29):3299-306
pubmed: 25185097
Cancer Metab. 2015 Jan 29;3(1):2
pubmed: 25635223
Pancreatology. 2017 Sep - Oct;17(5):833-838
pubmed: 28778480
World J Gastrointest Oncol. 2015 Sep 15;7(9):141-7
pubmed: 26380057
Radiat Oncol J. 2012 Mar;30(1):1-13
pubmed: 23120738
J Gastrointest Oncol. 2013 Dec;4(4):343-51
pubmed: 24294505
PLoS One. 2017 Oct 12;12(10):e0186341
pubmed: 29023527
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10756-10761
pubmed: 30201710
Radiother Oncol. 2004 Dec;73 Suppl 2:S161-9
pubmed: 15971335
Radiat Oncol. 2013 Jun 21;8:148
pubmed: 23799996
Oncotarget. 2017 Apr 4;8(14):23702-23712
pubmed: 28423594
J Gastrointest Surg. 2010 Oct;14(10):1547-59
pubmed: 20839073
J Gastroenterol. 2014 Jun;49(6):1074-80
pubmed: 23846547
Phys Med Biol. 2014 Nov 21;59(22):R419-72
pubmed: 25361443
PLoS One. 2014 Dec 02;9(12):e113591
pubmed: 25460352
Oncotarget. 2016 Jun 7;7(23):33571-80
pubmed: 27248663
Lancet Oncol. 2017 Aug;18(8):991-993
pubmed: 28651928
Cancer. 2015 Apr 1;121(7):1128-37
pubmed: 25538019
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1166-71
pubmed: 22543215
J Proteomics. 2018 Sep 30;188:107-118
pubmed: 29398619
J Gastrointest Oncol. 2018 Aug;9(4):687-693
pubmed: 30151265
Radiother Oncol. 2008 Jun;87(3):326-30
pubmed: 18342968
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):498-504
pubmed: 26883565
J Clin Oncol. 2011 Nov 1;29(31):4105-12
pubmed: 21969502
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3
pubmed: 16168826
JAMA Oncol. 2018 Jul 1;4(7):963-969
pubmed: 29800971
Transl Oncol. 2017 Oct;10(5):760-765
pubmed: 28778024
Radiother Oncol. 2011 May;99(2):108-13
pubmed: 21571383
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22
pubmed: 23562768
Cancer. 2013 Jan 1;119(1):45-51
pubmed: 22744973
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818783879
pubmed: 29962281
Cancers (Basel). 2018 Mar 06;10(3):
pubmed: 29509684
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):397-417
pubmed: 17478086
Med Phys. 2018 Nov;45(11):e1096-e1110
pubmed: 30421806
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):965-6
pubmed: 15752874
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S101-7
pubmed: 20171503
PLoS One. 2016 Jan 13;11(1):e0147113
pubmed: 26760500
Technol Cancer Res Treat. 2017 Jun;16(3):295-301
pubmed: 27311310
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8
pubmed: 24867540
Cancer Biol Ther. 2015;16(3):438-49
pubmed: 25679067
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):151-7
pubmed: 20421151
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1120-5
pubmed: 22099048
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):678-86
pubmed: 18395362
World J Gastrointest Surg. 2017 Apr 27;9(4):103-108
pubmed: 28503258
Radiother Oncol. 2019 Jul;136:37-43
pubmed: 31015127
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9
pubmed: 15145162
J Gastrointest Oncol. 2017 Oct;8(5):766-777
pubmed: 29184680
Radiother Oncol. 2018 Nov;129(2):333-339
pubmed: 30224179
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8
pubmed: 21549517
Radiat Oncol. 2012 May 18;7:74
pubmed: 22607687
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e615-22
pubmed: 21658854
J Clin Oncol. 2014 Sep 10;32(26):2855-63
pubmed: 25113772
J Clin Oncol. 2015 May 1;33(13):1475-81
pubmed: 25512461
BMC Cancer. 2013 Sep 14;13:419
pubmed: 24034562
Cancer Invest. 2012 Feb;30(2):149-55
pubmed: 22250589
Adv Radiat Oncol. 2018 Apr 13;3(3):314-321
pubmed: 30202800
Am J Clin Oncol. 2011 Feb;34(1):63-9
pubmed: 20308870
Acta Oncol. 2015 Jul;54(7):979-85
pubmed: 25734581
Clin Cancer Res. 2012 Feb 1;18(3):758-70
pubmed: 22184053
J Gastrointest Oncol. 2017 Aug;8(4):665-674
pubmed: 28890817
Pancreas. 2018 Apr;47(4):382-389
pubmed: 29521941
Ann Oncol. 2008 Sep;19(9):1592-9
pubmed: 18467316
Radiat Oncol. 2013 Mar 01;8:44
pubmed: 23452509
Oncogene. 2018 Feb 15;37(7):953-962
pubmed: 29059162
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21
pubmed: 15001240
JAMA. 2008 Mar 5;299(9):1019-26
pubmed: 18319412
BMC Cancer. 2016 Aug 17;16:644
pubmed: 27535748
Jpn J Radiol. 2018 Jul;36(7):456-461
pubmed: 29748836
Br J Radiol. 2017 Apr;90(1072):20160790
pubmed: 28181819
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1212-1221
pubmed: 29907490
Ann Surg Oncol. 2010 Aug;17(8):2092-101
pubmed: 20224860
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1183-1196
pubmed: 28721903
Clin Cancer Res. 2011 May 1;17(9):2997-3004
pubmed: 21415214
J Cancer. 2016 Jan 10;7(3):283-8
pubmed: 26918041
Radiother Oncol. 2005 Jul;76(1):48-53
pubmed: 15990186